UFP Technologies, Inc. (UFPT) Stock Analysis

Company Overview

UFP Technologies, Inc. operates as a manufacturer and designer of specialized solutions within the medical device sector, focusing on sterile packaging, engineered custom products, and protective drapes for robotic surgery and advanced wound care. The company functions within the broader Healthcare industry, specifically targeting the Medical Devices segment, which implies a high reliance on regulatory compliance and integration into complex hospital supply chains. As of the latest data, the organization maintains a market capitalization of $1.45B, generating annual revenue of $602.80M, and employs a workforce of 4,846 individuals. These valuation and revenue figures indicate that UFP Technologies, Inc. holds a significant position as a mid-to-large-cap entity with substantial operational scale, distinguishing it from smaller niche medical device manufacturers that may lack diversified product lines or extensive manufacturing capacity.

Financial Health

The company reported a trailing twelve-month revenue of $602.80M, with a corresponding net income of $68.31M and EBITDA reaching $112.18M. The substantial gap between the gross revenue figure and the net income reveals a cost structure where approximately 88.7% of revenue is consumed by costs of goods sold, operating expenses, and taxes, leaving a final profit that is roughly 11.3% of total sales. Free cash flow stands at $65.67M, which demonstrates the company's ability to generate liquidity from its core operations independent of non-cash accounting adjustments, providing a buffer for capital expenditures or debt servicing. The gross margin is recorded at 28.3%, suggesting a moderate pricing power and production efficiency typical of custom-engineered medical products, while the operating margin of 14.1% reflects the effectiveness of overhead management before interest and taxes. Furthermore, the profit margin of 11.3% indicates the final percentage of revenue that translates into bottom-line earnings available to shareholders. In terms of liquidity and solvency, the company holds $20.30M in cash against total debt of $154.48M, resulting in a debt-to-equity ratio of 36.45, which characterizes a balance sheet that is leveraged rather than conservative. Despite the debt level, the current ratio of 2.69 suggests robust short-term liquidity, as current assets are more than double current liabilities. Return on equity is calculated at 17.8%, indicating efficient use of shareholder capital, while the return on assets of 9.1% highlights the company's ability to generate income relative to its total asset base.

Valuation Assessment

Valuation metrics show a trailing P/E ratio of 21.54 compared to a forward P/E of 16.46, implying that the market expects earnings growth in the future that is high enough to compress the multiple, or alternatively, that current earnings are temporarily depressed relative to future expectations. The price-to-book ratio is stated at 3.43, which indicates that the market values the company at a significant premium over its book value, likely reflecting intangible assets such as intellectual property, brand reputation, and the high barriers to entry in the medical device space. Alternative valuation metrics include a price-to-sales ratio of 2.41 and an EV/EBITDA of 14.33, suggesting the stock is priced in line with peers but warrants attention to whether sales growth can sustain these multiples. Regarding trading range, the 52-week high is $274.93 and the 52-week low is $178.26, meaning the current market price sits within a range where the stock has experienced volatility but remains below its recent peak. The beta value is 1.15, indicating that the stock's price volatility is 15% higher than the broader market, which suggests a higher risk profile for risk-averse investors compared to the market average.

Growth & Income

Revenue growth year-over-year is recorded at 3.4%, while earnings growth year-over-year stands at 6.8%, indicating that profitability is expanding at a faster pace than top-line sales, which often implies improving operational efficiency or favorable pricing dynamics. Since the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders, a strategy that prioritizes retaining earnings for reinvestment into research and development, manufacturing expansion, or debt reduction rather than income distribution. This retention policy is consistent with the capital-intensive nature of the medical device industry, where ongoing investment in sterile packaging technology and robotic surgery solutions is necessary to maintain market share. Overall, the growth and income profile is defined by moderate revenue expansion, accelerating earnings growth, and a complete absence of dividend payments, focusing entirely on capital appreciation and internal business development.